These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37493067)

  • 1. Estimation of conditional power in the presence of auxiliary data.
    Li X; Yung G; Lin J; Zhu J
    Stat Med; 2023 Oct; 42(24):4319-4332. PubMed ID: 37493067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective analysis of conditional power assumptions in clinical trials with continuous or binary endpoints.
    Edwards JM; Walters SJ; Julious SA
    Trials; 2023 Mar; 24(1):215. PubMed ID: 36949524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates.
    Van Lancker K; Vandebosch A; Vansteelandt S
    Pharm Stat; 2020 Sep; 19(5):583-601. PubMed ID: 32248662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using surrogate information to improve confirmatory platform trial with sample size re-estimation.
    Zhong C; Li Q; Wu L; Lin J
    J Biopharm Stat; 2022 Jul; 32(4):547-566. PubMed ID: 35714331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conditional power and predictive power based on right censored data with supplementary auxiliary information.
    Sun L; Wan Y
    Stat Med; 2018 Aug; 37(18):2690-2699. PubMed ID: 29682770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size adjustment designs with time-to-event outcomes: A caution.
    Freidlin B; Korn EL
    Clin Trials; 2017 Dec; 14(6):597-604. PubMed ID: 28795844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conditional power in vaccine trials with seasonal variations.
    Tang X; Yan LK; Scott JA
    J Biopharm Stat; 2022 May; 32(3):427-440. PubMed ID: 35767382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seamless phase 2/3 design for trials with multiple co-primary endpoints using Bayesian predictive power.
    Yang J; Li G; Yang D; Wu J; Wang J; Gao X; Liu P
    BMC Med Res Methodol; 2024 Jan; 24(1):12. PubMed ID: 38233758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints.
    Zocholl D; Kunz CU; Rauch G
    Stat Methods Med Res; 2023 Sep; 32(9):1749-1765. PubMed ID: 37489267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Practical Perspective: Application of the Generalized Approach for Adaptive Design.
    Wang J; Li J; Shu Y; Su X
    Ther Innov Regul Sci; 2020 Jan; 54(1):167-170. PubMed ID: 32008229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When inferiority meets non-inferiority: implications for interim analyses.
    Bratton DJ; Williams HC; Kahan BC; Phillips PP; Nunn AJ
    Clin Trials; 2012 Oct; 9(5):605-9. PubMed ID: 22796636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and monitoring of clinical trials with an interim analysis and a negative binomial endpoint.
    Quan H; Xu Y; Liu Y; Chen X
    Contemp Clin Trials; 2024 Mar; 138():107467. PubMed ID: 38331382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size re-estimation in a superiority clinical trial using a hybrid classical and Bayesian procedure.
    Ciarleglio MM; Arendt CD
    Stat Methods Med Res; 2019 Jun; 28(6):1852-1878. PubMed ID: 29869564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extension of a conditional performance score for sample size recalculation rules to the setting of binary endpoints.
    Bokelmann B; Rauch G; Meis J; Kieser M; Herrmann C
    BMC Med Res Methodol; 2024 Jan; 24(1):15. PubMed ID: 38243169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional power and friends: The why and how of (un)planned, unblinded sample size recalculations in confirmatory trials.
    Kunzmann K; Grayling MJ; Lee KM; Robertson DS; Rufibach K; Wason JMS
    Stat Med; 2022 Feb; 41(5):877-890. PubMed ID: 35023184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size re-estimation in clinical trials.
    Wang P; Chow SC
    Stat Med; 2021 Nov; 40(27):6133-6149. PubMed ID: 34433225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reassessment of trial perspectives from interim data--a critical view.
    Bauer P; Koenig F
    Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim analysis incorporating short- and long-term binary endpoints.
    Niewczas J; Kunz CU; König F
    Biom J; 2019 May; 61(3):665-687. PubMed ID: 30694566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.